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Abstract
Background: As women go through menopause, serum estrogen decreases and
ferritin increases. Decreased serum estrogen is well known to cause detrimental
effects on bone health; however, data on the associations of serum ferritin with
BMD before and after menopause are still lacking. Therefore, this study aimed to
investigate the association between serum ferritin levels and BMD in
premenopausal and postmenopausal Korean women.
Methods: This study was performed using data from the 2008–2010 Korean
National Health and Nutrition Examination Survey, including 7300 women (4229
premenopausal and 3071 postmenopausal). BMD was measured using dual X-ray
absorptiometry at the femur and the lumbar spine, and serum ferritin levels were
measured by chemiluminescent immunoassay.
Results: Median serum ferritin levels in postmenopausal women were higher than
those in premenopausal women despite the same age ranges. Serum ferritin levels
were only significantly correlated with BMD on the lumbar spine (b520.189, p-
value50.005) in premenopausal women after adjusting confounding factors.
Additionally, BMD on the lumbar spine had tended to decrease as serum ferritin
quartiles increase (P for trend50.035) in premenopausal women after adjusting
confounding factors. On the other hand, there were no significant associations
between serum ferritin levels and BMD on the total femur and, femur neck in
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premenopausal women, and BMD on the total femur, femur neck, and lumbar spine
in postmenopausal women.
Conclusion: Increased serum ferritin levels were significantly associated with BMD
in premenopausal women, particularly on the lumbar spine, but not in
postmenopausal women.
Introduction
Ferritin is an essential component of the body, but many studies have stated that
ferritin that exceeds the normal physiological range may potentially cause health
problems in women. Excessive iron is toxic, causing cellular dysfunction mainly as
a powerful catalyst for the generation of highly toxic free radicals, which can
damage all molecular classes found in vivo [1]. Modifications in these molecules
are considered to cause adverse effects on diverse aspects of health, most notably,
decrease in bone mineral density (BMD), which must be carefully considered as
mortality due to osteoporotic hip fractures alone is the same as that from breast
cancer [2, 3].
Recently, there has been clinical evidence to support an association between
serum ferritin level and bone parameters. Researchers have concluded that higher
body iron stores are significantly associated with lower bone mass at various
skeletal sites and cause an increased prevalence of osteoporosis and fractures,
especially in women $45 years old [4]. However, menopausal status was not
considered as a factor that could potentially have a great effect in determining the
bone mass in women.
The reason why menopause should be considered while evaluating BMD on
women is that by going through this physiological phenomenon, women
eventually experience changes on two important growth-associated molecules in
their bodies [5]: decrease in estrogen and increase in ferritin. Estrogen deficiency
is well known to cause detrimental effects on bone health [6]. Additionally, serum
ferritin increases by 2–3 times during this period due to the lack of a major
mechanism of iron excretion [7], while menstrual blood decreases [8]. However,
as far as we know, there has been little data presented suggesting an association
between serum ferritin and the status of BMD in women based on menopausal
status.
Therefore, in this study, we observed differences in BMD on the total femur,
femur neck, and lumbar spine with respect to serum ferritin level, and attempted
to determine whether levels of serum ferritin have associations with BMD in
Korean premenopausal and postmenopausal women.
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Methods
Study population
This study was performed using data from the Korean National Health and
Nutrition Examination Survey (KNHANES) (2008–2010 data), specifically data
from the KNHANES IV survey (2008 and 2009 data) and the KNHANES V survey
(2010 data), all performed by the Korean Ministry of Health and Welfare.
KNHANES IV and V were each conducted over 3 years (2007–2009 and 2010–
2012, respectively) using a rolling sample survey that involved a complex,
stratified, multistage, probability-cluster survey of a representative sample of the
non-institutionalized civilian population in South Korea. Sampling units were
randomly selected, with 23 households from each primary sampling unit and 200
randomly selected sampling units, yielding 4600 households in 2008, whereas 192
sampling units were randomly selected, with 20 households from each primary
sampling unit, yielding 3840 households in 2009 and 2010. The survey was
composed of three parts: a health interview survey, a health examination survey,
and a nutrition survey. All surveys were conducted by trained interviewers. The
interviewers were not provided with any prior information regarding the specific
participants before performing the interviews. All participants were provided with
written informed consents to participate in this survey, and we received the data
in anonymized form. The study was carried out in accordance with the ethical
standards of the Helsinki Declaration, and was approved by the Yonsei University
Health System, Severance Hospital, Institutional Review Board (4-2013-0706).
We excluded male participants and individuals who were less than 20 years old,
pregnant, had aspartate aminotransferase (AST) or alanine aminotransferase
(ALT) levels greater than 100 IU/L, hemoglobin (Hb) levels less than 10 g/dL,
creatinine levels greater than 1.4 mg/dl, white blood cell (WBC) counts greater
than 10000Thous/ or less than 4000Thous/ or ones who suffered from
cardiovascular, liver, renal, or thyroid disease or cancer. In addition, participants
were excluded if they had not provided blood samples for ferritin measurement or
if their BMD on total femur, femur neck, and lumbar spine were not determined.
People with serum ferritin levels less than 1.0 ng/mL or greater than 500.0 ng/mL
were excluded to rule out those with possible ferritin-related disease such as
hemochromatosis or sickle cell disease. Women who did not undergo
anthropometric measurements of height and weight and ones who had undergone
hysterectomy or bilateral salpingo-oophorectomy were excluded. The final sample
consisted of 7,300 participants (4,229 premenopausal and 3,071 postmenopausal
women).
Variable measurements
Based on age, participants were grouped into 15 categories. Seoul (the capital city
of Korea) and its surrounding metropolitan area (Gyonggi), along with six other
cities (Incheon, Daejeon, Gwangju, Daegu, Busan, and Ulsan) were classified as
urban areas, whereas the remaining regions in South Korea were classified as rural
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areas. Subjects were classified as current smokers (if they had smoked at least one
cigarette per day during the previous 12 months), ever smokers, and never
smokers. Alcohol consumption was evaluated and categorized into four groups,
depending on history of drinking for the previous 12 months. Physical activity
levels were divided into three categories, low, moderate, and high, according to
the International Physical Activity Questionnaire short-form scoring protocol [9].
Education level was stratified into three categories: (1) elementary school (6 years
of schooling); (2) middle, high school (7–12 years of schooling); and (3) college or
university (.12 years of schooling). Occupation was classified into two categories:
(1) people who work regularly in an office or indoors and (2) people who usually
work outdoors and have rigorous physical activity. The circumstances of dietary
intake were classified into four groups to predict whether participants had been
supplied with sufficient nutrition (both quantity and quality) through their meals:
(1) frequently insufficient quantity and quality, (2) occasionally insufficient
quantity and quality, (3) sufficient quantity but poor quality, (4) sufficient
quantity with diverse nutritional supplementations. Personal and family histories
of bone fractures were surveyed, and HT usage was divided into two categories:
ever and never users.
Anthropometric measurements were performed. Height and weight were
measured with light clothing without shoes. Blood samples were collected early in
the morning, after overnight fasting. Plasma concentrations of hemoglobin,
vitamin D, ferritin, alkaline phosphatase (ALP), and parathyroid hormone (PTH)
were measured following routine biochemical laboratory protocols. Ferritin was
measured by chemiluminescent immunoassay with an ADVIA Centaur system
(Siemens, USA) until February 15, 2008, and immunoradiometric assay with a
1470 WIZARD gamma counter (Perkin Elmer, Finland) from February 16, 2008
until 2010. All clinical analyses were performed at the Neodin Medical Institute, a
laboratory certified by the Korean Ministry of Health and Welfare.
Criteria and Definitions
Menopause is defined as amenorrhea for 12 months following the final menstrual
period [10]. In our study, postmenopausal status was defined as the self-reported
cessation of menstruation for more than 1 year only because we had already
excluded women who had undergone hysterectomy or bilateral salpingo-
oophorectomy. Among postmenopausal women, women less than 40 years old
were excluded since they were not considered as physiologically menopaused
women. Although serum ferritin ranges can vary among laboratories, levels
exceeding 500.0 ng/mL were considered as a marker of iron overload disorders
[11]. Values of serum ferritin were divided according to quartiles for each group
of premenopausal and postmenopausal women. Osteoporosis is a systemic
skeletal disease characterized by low bone density and micro-architectural
deterioration of bone tissue with a consequent increase in bone fragility [12],
diagnosed primarily based on BMD. According to a WHO Study Group, the
diagnosis of osteoporosis among postmenopausal women is based on T-score
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thresholds. T-scores at or above -1.0 are considered normal, those between 21.0
and 22.5 as osteopenia, and those at or below 22.5 as osteoporosis [13].
Statistical analysis
To analyze baseline characteristics according to menopausal status, data were
expressed as means (¡ standard deviation; SD) for continuous variables after
independent-sample t test and as percentages for categorical variables after chi
square test, unless otherwise stated. One-way analysis of variance (ANOVA) was
used to express graphs comparing serum ferritin values according to age groups
depending on menopausal status. In order to compare BMD values on total
femur, femur neck and lumbar spine according to serum ferritin quartiles after
adjustment for confounding variables, analysis of covariance (ANCOVA) was
used in premenopausal and postmenopausal women separately. We used simple
linear logistic regression model to determine the independent effects of serum
ferritin on BMD at various skeletal sites among premenopausal and postmeno-
pausal Korean women. The covariates for the adjusted calculation were age, body
mass index (BMI), smoking, drinking, exercise, serum vitamin D, and calcium
and phosphate supplementation. Data analysis was carried out using SPSS
software (version 20; SPSS, Chicago, IL), and p-values less than 0.05 were
considered significant.
Results
Table 1 shows baseline characteristics of premenopausal and postmenopausal
women. BMI, serum ferritin, and vitamin D were statistically significantly higher
in postmenopausal women than in premenopausal women, whereas calcium and
phosphate supplementations and BMD on total femur, femur neck, and lumbar
spine were lower in postmenopausal women than in premenopausal women (p-
value,0.001).
Fig. 1 shows median serum ferritin levels according to age groups depending on
menopausal status. As women became older, the median serum ferritin levels
showed tendency to increase. After dividing women into two groups depending
on menopausal status, the median serum ferritin in premenopausal women was
found to be much lower than that in postmenopausal women, which was
particularly notable in the overlapping age groups, between 40–59 years old.
To determine the associations in between serum ferritin and BMD at various
skeletal sites, simple linear logistic regression analysis was performed after
adjusting for age, BMI, smoking, drinking, exercise, serum hydroxyvitamin D
levels, calcium and phosphate supplementations, personal and family histories of
bone fractures. In premenopausal women, BMD on total femur and femur neck
were not associated with differences in serum ferritin, whereas statistically
significant decrease in BMD on lumbar spine was noted as serum ferritin
increased (b520.189, p-value50.005). On the other hand, no statistically
Serum Ferritin and BMD in Premenopausal and Postmenopausal Women
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Table 1. Baseline characteristics of premenopausal and postmenopausal women.
Premenopause (n54229) Postmenopause (n53071) p-value
Age (years) 36.45¡8.50 63.63¡9.22 ,0.001
Height (cm) 159.35¡5.57 153.02¡5.84 ,0.001
Weight (kg) 57.40¡9.19 56.68¡8.58 0.001
BMI (kg/m2) 22.61¡3.44 24.17¡3.20 ,0.001
Hb (g/dL) 12.83¡1.18 13.11¡0.97 ,0.001
Serum Ferritin (ng/mL) 32.22¡27.64 68.22¡47.70 ,0.001
Serum Vitamin D (ng/mL) 16.44¡5.80 19.10¡7.27 ,0.001
Serum ALP (IU/L) 183.24¡52.85 253.36¡74.48 ,0.001
Serum PTH (pg/mL) 66.67¡23.49 68.13¡29.87 0.446
Ca intake/day (mg) 467.06¡300.56 419.17¡392.40 ,0.001
P intake/day (mg) 1042.90¡435.36 945.38¡430.67 ,0.001
Total femur BMD (g/cm2) 0.90¡0.11 0.77¡0.12 ,0.001
Femur neck BMD (g/cm2) 0.76¡0.10 0.62¡0.11 ,0.001
Lumbar spine BMD (g/cm2) 0.99¡0.12 0.80¡0.14 ,0.001
Resident district ,0.001
Urban 2968 (70.2) 179 (58.4)
Rural 1261 (29.8) 1279 (41.6)
Education ,0.001
Elementary 186 (4.4) 2039 (67.0)
Middle, High school 2301 (54.6) 880 (28.9)
University, College 1729 (41.0) 126 (4.1)
Occupation ,0.001
Office type 3851 (91.5) 2178 (71.6)
Outfield type 360 (8.5) 866 (28.4)
Alcohol ,0.001
Never 2163 (51.3) 2523 (82.4)
#Once/month 1578 (37.4) 418 (13.7)
.Once/month, #Once/week, 395 (9.4) 85 (2.8)
.Once/week, #Everyday 84 (2.0) 35 (1.1)
Smoking ,0.001
Never 3638 (88.5) 2790 (92.4)
Ever 193 (4.7) 95 (3.1)
Current 280 (6.8) 136 (4.5)
Physical activity 0.001
Low 2684 (63.7) 2071 (67.9)
Moderate 890 (21.1) 600 (19.7)
High 640 (15.2) 381 (12.5)
Dietary intake ,0.001
Frequently difficult 14 (0.4) 57 (2.0)
Occasionally difficult 107 (2.8) 239 (8.5)
Enough, but not diverse 1932 (50.3) 1569 (55.5)
Diverse, Enough 1790 (46.6) 960 (34.0)
Personal history of fracture ,0.001
Yes 101 (2.4) 637 (20.7)
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significant correlations were found in serum ferritin and BMD at any parts of
skeletal sites in postmenopausal women (Table 2).
After categorizing pre and postmenopausal women into four groups according
to numbers of people having various serum ferritin concentrations [0.680–
19.110 ng/mL for Q1, 19.120–37.690 ng/mL for Q2, 17.691–62.930 ng/mL for Q3,
and 62.931–486.110 ng/mL for Q4], ANCOVA was used in order to investigate
BMD at various skeletal sites according to serum ferritin quartiles after adjusting
confounding variables. Only lumbar spine in premenopausal women showed
significantly decreased tendency in BMD as serum ferritin increased in quartiles
Table 1. Cont.
Premenopause (n54229) Postmenopause (n53071) p-value
Family history of fracture 0.797
Yes 723 (17.1) 518 (16.9)
HT ,0.001
No 4138 (97.8) 2637 (85.9)
Yes 91 (2.2) 434 (14.1)
BMI: Body mass index, Hb: Hemoglobin, ALP: Alkaline phosphatase, PTH: Parathyroid hormone, Ca: Calcium, P: Phosphate, BMD: Bone mineral density,
HT: Hormonal therapy.
Reference range: Hb 12.0–16.0 g/dL; Ferritin 10.0–130.0 ng/mL; Vitamin D 30.0–100.0 ng/mL; ALP 39.0–117.0 IU/L; PTH 10.0–57.0 pg/mL.
doi:10.1371/journal.pone.0114972.t001
Fig. 1. Median serum ferritin concentrations according to age group. As women become older, the
median serum ferritin levels showed tendency to increase. After dividing women into two groups depending on
menopausal status, the median serum ferritin in premenopausal women was found to be much lower than that
in postmenopausal women, in between 40–59 years old.
doi:10.1371/journal.pone.0114972.g001
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(P for trend50.035). On the other hand, BMD on total femur and femur neck (P
for trend50.903, 0.890, respectively) in premenopausal women (Fig. 2), BMD on
total femur, femur neck, and lumbar spine in postmenopausal women were not
found to be statistically significantly associated (P for trend50.396, 0.160, 0.793,
respectively) (Fig. 2).
Discussion
We investigated the associations of serum ferritin with BMD based on
menopausal status, which is a period when some people face detrimental effects
on bone health. In the present study, an increase in serum ferritin was statistically
significantly associated with a decrease in BMD on the lumbar spine; however, no
statistically significant associations were found on the total femur and femur neck
in premenopausal women. Conversely, no associations were found for serum
ferritin with BMD on various skeletal sites in postmenopausal women.
Ferritin is a ubiquitous intracellular protein that provides stored iron in a non-
toxic form, and ferritin levels reflect the amount of iron stored in the body. When
levels of serum iron increase, the level of transferrin is not up-regulated, meaning
that all iron molecules are not able to bind to transferrin. In an iron overloaded
status, leftover iron that is not bound to transferrin may cause detrimental effects
on tissues. Two main hypotheses attempt to explain this toxicity induced by iron
overload: oxidative injury and lysosomal injury. The oxidative injury hypothesis
proposes that iron overload in vivo results in the formation of oxyradicals, which
damage cellular constituents including lipids, nucleic acids, proteins, and
carbohydrates and impair calcium homeostasis and cellular function [14]. The
lysosomal injury hypothesis proposes that excessive accumulation of iron within
lysosomes can lead to lysosomal fragility, impairing lysosomal function through
the release of hydrolytic enzymes and storing iron into the cytoplasm [14].
Progressive iron deposition can also result in cardiac, hepatic, and endocrine
disorders [15, 16]. Endocrine dysfunction is a consequence of iron overload in
hypothalamic-pituitary axis, and frequently manifests with abnormalities in
pubertal development and menstrual irregularities in females [17].
A decrease of BMD has been considered to be a disease associated with
abnormal calcium metabolism. Additionally, an increasing number of studies
Table 2. Logistic regression analysis to determine the effects of serum ferritin on bone mineral density at various skeletal sites.
Premenopause (n54229) Postmenopause (n53071)
Variables b SE(b) p-value b SE(b) p-value
Total femur (g/cm2) 20.046 0.059 0.439 0.008 0.036 0.823
Femur neck (g/cm2) 20.044 0.059 0.456 0.007 0.034 0.840
Lumbar spine (g/cm2) 20.189 0.068 0.005 0.063 0.047 0.185
Adjusted variables: age, BMI, smoking, drinking, exercise, serum 25-hydroxyvitamin D levels, calcium and phosphate supplementations, personal history of
fracture, family history of fracture.
doi:10.1371/journal.pone.0114972.t002
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have strongly been suggesting the deleterious role of excessive iron on bone health
[18]. In cases of hemochromatosis [19], African hemosiderosis [20], thalassemia
[21], sickle cell disease [22, 23], and liver diseases [24, 25], iron overload could be
suggested as a common mechanism causing bone loss. For example, in genetic
hemochromatosis, osteopenia, and osteoporosis have been observed in 78.9% and
34.5% of patients with iron overloaded condition, respectively [26]. One previous
study reported that sickle cell disease leads to many complications including
osteoporosis and osteopenia, correlating especially strongly with increased ferritin
level [27]. Likewise, overloaded iron acts in diverse ways, inhibiting osteoblast
differentiation, stimulating osteoclast resorption, decreasing activity of alkaline
phosphatase (ALP) which is an important enzyme in early osteogenesis [15], and
also inhibiting anterior pituitary synthesis of gonadotropins [28]. On the other
hand, there are also studies on contradictory results. In a previous animal study,
dietary iron deficiency was also reported to affect bone negatively [29], and
another report showed that osteoporosis patients are slightly iron deficient,
suggesting that serum ferritin levels do not always have to be high to have
detrimental effects on bone metabolism [30].
Fig. 2. BMD according to serum ferritin quartiles after adjusting with confounders in premenopausal and postmenopausal women. Only lumbar
spine in premenopausal women showed significantly decreased tendency in BMD as serum ferritin increased in quartiles (P for trend50.035). On the other
hand, BMD on total femur and femur neck (P for trend50.903, 0.890, respectively) in premenopausal women. BMD on total femur, femur neck, and lumbar
spine in postmenopausal women were not found to be statistically significantly associated (P for trend50.396, 0.160, 0.793, respectively).
doi:10.1371/journal.pone.0114972.g002
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As previously mentioned, serum ferritins increase by 2–3 times during the
menopausal period [31]. Given that overloaded serum ferritin, which is known to
be a source of decrease in BMD, is more profound in postmenopausal women, we
speculated that an increase in serum ferritin would cause more cases of
osteoporosis in postmenopausal women. However, the outcome of our study was
different from expected, with results presenting a statistically significant decrease
on lumbar spine BMD as serum ferritin levels increased only in premenopausal
women, whereas no significant associations were noted for serum ferritin with
BMD of the total femur, femur neck and lumbar spine in postmenopausal
women. Therefore, it is not serum ferritin which is important; rather it is the
change in serum ferritin level that is important in interpreting associations with
BMD, which we can also see from another previous large longitudinal study [32].
Postmenopause, associated with the loss of bone due to the anabolic and
antiresorptive effects of ovarian hormones, has long been recognized as a risk for
osteoporosis [33, 34]. The most rapid bone losses occur in menopausal transition
and before menstrual cycles have completely stopped. Recently a number of
studies have observed accelerated bone density loss in perimenopausal women
prior to their menopause [35, 36], and longitudinal studies have also shown
particularly high bone density loss during perimenopause and its continuation
during the first few years of postmenopause [35, 37, 38]. In one previous study,
higher estrogen levels were significantly correlated with less average bone density
loss in premenopausal, perimenopausal and postmenopausal women [39]. For the
first few years of menopause, serum ferritin levels do not seem to have an impact
on BMD, but after a certain periods of time, increase in serum ferritin levels seem
to affect decrease in BMD among postmenopausal women.
In our study, a statistically significant decrease in BMD was found only on the
lumbar spine in premenopausal women. The lumbar spine is classified as
trabecular bone, in which the mineralized bone matrices are rapidly lost because
their large surface areas facilitate remodeling and their thin plates of mineralized
matrix are easily perforated, resulting in the loss of trabecular connections
[40, 41]. This high surface area-bone matrix volume configuration provides a
large area facilitating the initiation of remodeling of the smaller mineralized
trabecular bone matrix volume [39]. In a previous longitudinal population-based
study, the rate of bone loss from the axial skeleton in women was found to be
similar before and after 50 years of age, whereas bone loss at appendicular sites did
not begin until midlife [42]. Also, in additional cross-sectional and longitudinal
population-based studies, researchers confirmed that cortical volumetric BMD
remained relatively stable until menopause and then decreased significantly,
whereas trabecular bone loss began early, in the third decade and accelerated after
menopause [43].
The age group of 45–55 years old is the most heterogeneous age group
consisting of both premenopausal and postmenopausal women. Although in the
same age group, premenopausal women have lower levels of serum ferritin with
higher BMD, whereas postmenopausal women have higher levels of serum ferritin
with lower BMD. Therefore, regardless of menopausal status, it is not appropriate
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to draw a conclusion, stating that women $45 years of age have serum ferritin
levels which significantly associate with bone parameters [4], based on
heterogeneous data.
The present study has some limitations. As this study is cross-sectional, direct
associations between the variables of interest could not be clearly determined.
Additionally, if we could have collected information on other factors that may
have affected serum ferritin and BMD, we would have achieved more precise
results. Furthermore, because we collected data retrospectively, we were unable to
measure variables in a serial manner, which may have led to less accurate results.
However, as this study was performed using a representative sample of the general
South Korean population, and rigorous quality controls were applied to the study
procedures in KNHANES, we believe that the data is valuable and should be taken
into consideration. Also, since the latitude of South Korea ranges from 33 to 38
degrees north, all the people would not have been exposed to environments
suitable for making adequate amounts of vitamin D from sunlight by themselves.
Therefore, a geographic factor should also be taken as a meaningful adjusted
variable. Moreover, by accounting for menopausal status, associations of serum
ferritin with BMD would have been logically established.
In conclusion, increased serum ferritin levels were statistically significantly
associated with a decrease in BMD of the lumbar spine in Korean premenopausal
women, whereas no associations were found for serum ferritin with BMD of the
total femur, femur neck and lumbar spine in women after menopause. This could
be due to the fact that although increased serum ferritin is a well-documented
change in postmenopausal women, there may be more comprehensive changes
caused by menopause itself, which would affect BMD more profoundly.
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